{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T01:10:24Z","timestamp":1754183424468,"version":"3.41.2"},"reference-count":34,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0639","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T18:07:28Z","timestamp":1748542048000},"page":"947-957","source":"Crossref","is-referenced-by-count":0,"title":["Esaxerenone improves the blood pressure and metabolic parameters of hypertensive subjects with diabetes"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7652-2567","authenticated-orcid":false,"given":"Saki","family":"Kuwabara","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-6688","authenticated-orcid":false,"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Yokozeki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aika","family":"Miya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-221X","authenticated-orcid":false,"given":"Hiroshi","family":"Nomoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"},{"name":"Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Yong","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohide","family":"Koyanagawa","sequence":"additional","affiliation":[{"name":"Shiomidai Clinic, Otaru, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, and Diabetes, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Sapporo Diabetes and Thyroid Clinic, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So","family":"Nagai","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Department of Medicine, NTT Medical Center Sapporo, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5839-7448","authenticated-orcid":false,"given":"Arina","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9796-4890","authenticated-orcid":false,"given":"Norio","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Taneda","sequence":"additional","affiliation":[{"name":"Manda Memorial Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Kurihara Clinic, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. (2013) 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159\u20132219.","DOI":"10.1093\/eurheartj\/eht151"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Iimura O (1996) Insulin resistance and hypertension in Japanese. Hypertens Res 19 Suppl 1: S1\u2013S8.","DOI":"10.1291\/hypres.19.SupplementI_S1"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, et al. (2008) Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51: 1403\u20131419.","DOI":"10.1161\/HYPERTENSIONAHA.108.189141"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16: 434\u2013444.","DOI":"10.2337\/diacare.16.2.434"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Nakamura Y, Yamamoto T, Okamura T, Kadowaki T, Hayakawa T, et al. (2006) Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980\u20131994. Circ J 70: 960\u2013964.","DOI":"10.1253\/circj.70.960"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kengne AP, Patel A, Barzi F, Jamrozik K, Lam TH, et al. (2007) Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 25: 1205\u20131213.","DOI":"10.1097\/HJH.0b013e3280dce59e"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, et al. (2015) Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol 14: 133.","DOI":"10.1186\/s12933-015-0296-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Barnett AH (1994) Diabetes and hypertension. Br Med Bull 50: 397\u2013407.","DOI":"10.1093\/oxfordjournals.bmb.a072899"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9 DeFronzo RA (1981) The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia 21: 165\u2013171.","DOI":"10.1007\/BF00252649"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Weidmann P, Beretta-Piccoli C, Keusch G, Gl\u00fcck Z, Mujagic M, et al. (1979) Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med 67: 779\u2013784.","DOI":"10.1016\/0002-9343(79)90734-4"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Christlieb AR, Janka HU, Kraus B, Gleason RE, Icasas-Cabral EA, et al. (1976) Vascular reactivity to angiotensin II and to norepinephrine in diabetic subjects. Diabetes 25: 268\u2013274.","DOI":"10.2337\/diabetes.25.4.268"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Jia G, Lockette W, Sowers JR (2021) Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease. Am J Physiol Regul Integr Comp Physiol 320: R276\u2013R286.","DOI":"10.1152\/ajpregu.00280.2020"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Funder JW (1995) Mineralocorticoid receptors and hypertension. J Steroid Biochem Mol Biol 53: 53\u201355.","DOI":"10.1016\/0960-0760(95)00021-Q"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Shibata H, Itoh H (2012) Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 25: 514\u2013523.","DOI":"10.1038\/ajh.2011.245"},{"key":"15","unstructured":"15 (2008) Aldactone<sup>\u00ae<\/sup> (spironolactone). US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/012151s062lbl.pdf accessed on June 20, 2024."},{"key":"16","unstructured":"16 (2002) INSPRA<sup>\u00ae<\/sup> (eplerenone). US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21437lbl.pdf accessed on June 20, 2024."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, et al. (2022) Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension 79: 2685\u20132695.","DOI":"10.1161\/HYPERTENSIONAHA.122.19744"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18 Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, et al. (2020) Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension 75: 51\u201358.","DOI":"10.1161\/HYPERTENSIONAHA.119.13569"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S (2019) Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res 42: 1932\u20131941.","DOI":"10.1038\/s41440-019-0314-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S (2019) Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res 42: 1572\u20131581.","DOI":"10.1038\/s41440-019-0270-2"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21 American Diabetes Association Professional Practice Committee (2024) 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care 47: S20\u2013S42.","DOI":"10.2337\/dc24-S002"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Motoki H, Inobe Y, Fukui T, Iwasaki A, Hiramitsu S, et al. (2023) Efficacy and safety of esaxerenone in hypertensive patients with diabetes mellitus undergoing treatment with sodium-glucose cotransporter 2 inhibitors (EAGLE-DH). Adv Ther 40: 5055\u20135075.","DOI":"10.1007\/s12325-023-02633-8"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23 Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, et al. (2010) Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 151: 2040\u20132049.","DOI":"10.1210\/en.2009-0869"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Wada T, Miyashita Y, Sasaki M, Aruga Y, Nakamura Y, et al. (2013) Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab 305: E1415\u2013E1425.","DOI":"10.1152\/ajpendo.00419.2013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Johansen ML, Schou M, Rossignol P, Holm MR, Rasmussen J, et al. (2019) Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial). Diabetes Obes Metab 21: 2305\u20132314.","DOI":"10.1111\/dom.13809"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, et al. (2020) Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol 15: 1715\u20131727.","DOI":"10.2215\/CJN.06870520"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Uchida HA, Nakajima H, Hashimoto M, Nakamura A, Nunoue T, et al. (2022) Efficacy and safety of esaxerenone in hypertensive patients with diabetic kidney disease: a multicenter, open-label, prospective study. Adv Ther 39: 5158\u20135175.","DOI":"10.1007\/s12325-022-02294-z"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, et al. (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323\u2013334.","DOI":"10.1056\/NEJMoa1515920"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, et al. (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347\u2013357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, et al. (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7: 606\u2013617.","DOI":"10.1016\/S2213-8587(19)30180-9"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, et al. (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383: 1425\u20131435.","DOI":"10.1056\/NEJMoa2004967"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, et al. (2021) Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia 64: 1256\u20131267.","DOI":"10.1007\/s00125-021-05407-5"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Oshima A, Imamura T, Narang N, Kinugawa K (2021) Renoprotective effect of the mineralocorticoid receptor antagonist esaxerenone. Circ Rep 3: 333\u2013337.","DOI":"10.1253\/circrep.CR-21-0024"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/8\/72_EJ24-0639\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T03:33:46Z","timestamp":1754105626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/8\/72_EJ24-0639\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0639","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"type":"print","value":"0918-8959"},{"type":"electronic","value":"1348-4540"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0639"}}